Medicare Payment Demo Would Put Often-Prescribed Cancer Drugs ‘Underwater’
Executive Summary
Community oncology practices and hospitals strongly object to CMS’ plan for testing different reimbursement formula Part B drugs, which is expected to particularly impact treatments for cancer, arthritis and eye disease.
You may also be interested in...
CMS Cancels Part B Demo Before HHS Secretary-Designate Price Does
President-elect Trump’s selection for HHS secretary, Rep. Tom Price, R-Ga., has been an outspoken critic of the proposed Medicare Part B drug demonstration project.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Khan Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.